Scientists hunt for clues in blood and tumors to predict Cancer's next move
NCT ID NCT07507578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study aims to understand why metastatic adenoid cystic carcinoma (ACC) of the head and neck behaves differently in different people. Researchers will analyze stored tumor tissue and blood samples from 114 adults to see if certain biological types (ACC-I or ACC-II) are linked to how fast the cancer grows. No experimental treatment is given; participants continue their usual care while providing samples every 6 months for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal biological markers that help doctors predict how aggressive a patient's cancer will be and guide future personalized treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants, and the findings may not lead to new therapies for many years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target multiple Hard-to-Treat cancers?
- New targeted pill holds promise for rare salivary gland cancer that spreads
- New combo therapy takes aim at Hard-to-Treat salivary gland cancer
- GPS for surgeons: new navigation tool aims to improve head and neck cancer outcomes
- Microchip implant could personalize cancer drug selection